A Prospective, Randomized, Double Dummy, Double Blind, Multinational, Multicenter Trial Comparing the Safety and Efficacy of Sequential (Intravenous/Oral) Moxifloxacin 400 mg OD to Intravenous Piperacillin/Tazobactam 4.0/0.5 g Every 8 Hours Followed by Oral Amoxicillin/Clavulanic Acid Tablets 875/125 mg Every 12 Hours for the Treatment of Subjects With Complicated Skin and Skin Structure Infections.

Trial Profile

A Prospective, Randomized, Double Dummy, Double Blind, Multinational, Multicenter Trial Comparing the Safety and Efficacy of Sequential (Intravenous/Oral) Moxifloxacin 400 mg OD to Intravenous Piperacillin/Tazobactam 4.0/0.5 g Every 8 Hours Followed by Oral Amoxicillin/Clavulanic Acid Tablets 875/125 mg Every 12 Hours for the Treatment of Subjects With Complicated Skin and Skin Structure Infections.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Sep 2014

At a glance

  • Drugs Amoxicillin/clavulanic acid; Moxifloxacin; Moxifloxacin; Piperacillin/tazobactam
  • Indications Abscess; Diabetic foot ulcer; Escherichia coli infections; Skin and soft tissue infections; Staphylococcal infections
  • Focus Registrational; Therapeutic Use
  • Acronyms RELIEF
  • Sponsors Bayer; Bayer HealthCare
  • Most Recent Events

    • 24 Sep 2010 Results from a sub-study in patients with diabetic foot infections were presented at the 46th Annual Meeting of the European Association for the Study of Diabetes.
    • 13 Apr 2010 Results from a sub-study in patients with diabetic foot ulcer have been presented at the 20th European Congress of Clinical Microbiology and Infectious Diseases.
    • 18 May 2009 Results have been reported at the 19th European Congress of Clinical Microbiology and Infectious Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top